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CHAPTER ONE 
Introduction 
1.1 Neurotransmission 
The brain is the most complex organ in the human and animal 
body. The human brain is comprised of 100 billion neurons with trillions 
of synapses.2 Neurons consist of a cell body, which contains the nucleus 
and cytoplasmic organelles, surrounded by small dendritic branches and 
an axon through which an action potential is propagated to the axon 
terminals. A neuron’s function is specialized for different tasks based on 
the neurotransmitter(s) it expresses and the brain regions it innervates. 
Since neurons are not directly interconnected, adjoining neurons 
communicate chemically through junctions called synapses (Figure 1-1). 
This chemical communication is accomplished using neurotransmitters, 
which are biogenic chemicals released from neurons into the synapse.1 
There are many classes of neurotransmitters, such as amino acids, 
peptides, and monoamines.1  
Neurotransmitters are synthesized in the cytoplasm of the neuron 
and are stored in vesicles, found near the plasma membrane of the nerve 
terminal. Upon propagation of a signal, the membrane is depolarized via 
the influx of positive ions into the cell through membrane-bound ion 
channels, which causes the inside of the membrane to be more positive. 
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When the depolarization is sufficient to create an action potential, an 
influx of Ca2+ will be triggered at the nerve terminal, promoting fusion of 
vesicles to the pre-synaptic plasma membrane and release of 
neurotransmitters into the synapse. This process is called exocytosis. 
Released neurotransmitters can diffuse across the synaptic cleft and bind 
to specific receptors on the postsynaptic neuron, which leads to an 
electrical or biochemical alteration in the postsynaptic cell. 
Neurotransmitters are cleared from the synaptic cleft, which terminates 
the action of the neurotransmitter, by plasma membrane transporters on 
pre- or post-synaptic terminals. Following transporter-mediated uptake, 
the neurotransmitter can be recycled and be repackaged into vesicles. 
Additionally, neurotransmitters in the synaptic cleft can be enzymatically 
degradated or transported to neighboring glial cells.1 
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Figure 1-1. An illustration of a synapse 
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1.2 Amino Acid Neurotransmitters  
The amino acid family of neurotransmitters can be divided into two 
sub-groups: excitatory and inhibitory amino acid transmitters.2 Excitatory 
amino acids, including glutamate, aspartate, cysteate and homocysteate, 
stimulate neurotransmission by permitting an excess of positive charge 
inside the neuron resulting in depolarization of the neuron. On the other 
hand, inhibitory amino acids, including gamma amino butyric acid 
(GABA), glycine, and taurine, produce synaptic inhibition (i.e. 
hyperpolarization) by permitting a net positive charge to flow out of the 
cell or by making the cell membrane negatively charged.1, 2 In the central 
nervous system (CNS), the most abundant inhibitory and excitatory amino 
acid neurotransmitters are GABA (Figure 1-2A) and glutamate (Figure 1-
2B), respectively.2 In comparison, the concentration of GABA and 
glutamate in the brain is in the range of µmoles/gm, where as the 
concentration of monoamines are in the range of nmoles/gm.2  
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Figure 1-2. Representative amino acid chemical structures. (A) Chemical 
structure of the excitatory amino acid glutamate. (B) Chemical structure 
of the inhibitory amino acid gamma aminobutyric acid (GABA).  
 
A B 
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Gamma-aminobutyric acid 
GABA is a non-protein amino acid that is heterogeneously 
distributed throughout the brain, with the highest concentrations in the 
substantia nigra, hippocampus, hypothalamus, and the basal ganglia.2, 3 
GABA signaling regulates many neurological processes and 30-40% of all 
synaptic terminals contain GABA.3 
GABA is synthesized from alpha-ketoglutarate, which is an 
intermediate of the citric acid cycle. During the synthesis, alpha-
ketoglutarate is converted into glutamate by the action of GABA 
transaminase (GABA-T), which is then catalyzed by glutamate acid 
decarboxylase (GAD) to produce GABA1 (Figure 1-3). Like other 
neurotransmitters, GABA is packaged into vesicles in the presynaptic 
terminal and is released into the synaptic cleft following depolarization of 
the neuron. In the synaptic cleft, the released GABA is available to couple 
with membrane associated receptors found pre- and post-synaptically.1  
There are two major types of GABA receptors: GABAA, which is an 
ionotropic receptor where the GABA binding site is incorporated with a 
chloride ion channel and GABAB, which is a metabotrophic, G-protein 
coupled receptor consisting of seven transmembrane domains.3 
GABAA receptors are predominantly found post-synaptically. Upon 
activation, GABAA receptors increase membrane permeability to chloride 
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ions, leading to hyperpolarization of the neuron and inhibition of action 
potential propagation through the post-synaptic neuron. The inhibition of 
neuronal signaling mediated by GABAA receptors is rapid, occurring in 1 
to 10 ms, and sensitive to low concentration of GABA.1 The action of 
GABAA receptors can be selectively inhibited by the competitive 
antagonist, bicuculline.1,2  
GABAB receptors are mostly presynaptic and, like other 
metabotrophic receptors, they regulate cellular metabolic processes 
through phosphorylation of protein kinases and activation of second 
messengers.1 Since GABAB receptors are extrasynaptic (outside the 
synapse), they require higher concentrations of GABA to diffuse away from 
the synaptic cleft to bind and activate them. When located on pre-synaptic 
GABAergic terminals, extrasynaptic GABAB receptors act as autoreceptors, 
whose activation inhibits further synaptic release of GABA. GABAB 
receptors can also be located on glutamatergic nerve terminals, where 
they act as heteroreceptors, which inhibit the release of glutamate upon 
GABA activation. For example, baclofen is a competitive agonist which 
interacts with the GABA binding site of GABAB receptors to activate 
receptor function. Alternatively, GABAB function can be inhibited by the 
competitive antagonist, phaclofen.   
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Extraneuronal GABA is removed from the synaptic cleft by plasma 
membrane GABA transporters and repackaged into vesicles in GABAergic 
nerve terminals.4 GABA uptake can also be mediated by glial cells. Similar 
to neurons, GABA taken up in glial cells is converted into succinic acid 
semialdehyde by the action of GABA transaminase. Removal of the amino 
group of GABA is accepted by α-ketoglutarate to generate glutamic acid 
and thereby conserve the available supply of GABA. However, glutamic 
acid formed in glial cells cannot be converted to GABA since glial cells lack 
GAD. Rather, it is transported into the neuron, which regenerates GABA 
by the action of GAD to be packaged into vesicles for future release.     
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Figure 1-3.  The metabolic pathway of GABA synthesis and degradation  
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Glutamate  
Glutamate is the major stimulatory neurotransmitter, as it is found 
in over half of the synapses in CNS.3 As such, glutamate has important 
physiological roles in regulating synaptic plasticity, cognitive processes, 
learning and memory.1, 2 Neuronal glutamate is mainly synthesized from 
glucose through the Krebs cycle and transamination of α-keto-glutarate, 
since glutamate is unable to cross the blood-brain barrier.3 In the 
cytoplasm, glutamate is synthesized from glutamine by the action of 
glutaminase (Figure 1-4). 
Like other neurotransmitters, glutamate is stored in vesicles, 
released in a Ca2+-dependent manner following stimulation by a nerve 
impulse, and binds to specific receptors on the neuronal membrane.2 
There are two types of glutamate receptors: the ionotropic receptors have a 
glutamate binding site and an ion channel incorporated into the same 
complex and the metabotropic receptors are coupled to heterotrimeric G-
proteins.1, 2 
The three glutamate ionotropic receptors; N-methyl-D-aspartate 
(NMDA), α-amino-3-hydroxy-5-methyl-4-isoazole propionic acid (AMPA), 
and kainite receptors; are named based on the ability of these drugs to act 
as selective agonists.2 When glutamate binds to these receptors, it causes 
the Na+ ion channel coupled to the receptor to open. By increasing the 
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membrane permeability to Na+ ions, glutamate promotes depolarization of 
the neuronal membrane and excitation of neurons. 2 Like GABA ionotropic 
receptors, glutamate ionotropic receptors also mediate fast transmission.  
 Like other metabotropic receptors, glutamate metabotropic 
receptors (mGluRs) regulate intracellular protein kinase cascades, which 
affect cellular metabolic processes. There are eight different types of 
glutamate metabotropic receptors, named mGluR1 through mGluR8, 
depending on their amino acid sequence. mGluRs are located on the post-
synaptic membrane, where they regulate various ligand- and voltage-gated 
ion channels to promote neuronal depolarization. However, since mGluRs 
are not directly coupled to ion channels, neuronal excitation occurs on a 
much slower timescale following glutamate activation compared to 
ionotropic receptors.   
 The concentration of glutamate in the extracellular environment is 
primarily regulated through uptake via glutamate transporters on 
adjoining glial cells. In glial cells, glutamate is converted into glutamine by 
glutamine synthetase before being transported out of the cell. This 
glutamine is taken up by glutamatergic neurons and subsequently 
reconverted into glutamate by glutaminase.1   
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Figure 1-4. Neuronal synthesis and degradation of glutamate. Cytosolic 
glutamate (glu) is synthesized from glutamine (gln) by the enzyme 
glutaminase, where cytosolic glu is stored in synaptic vesicles. After an 
action potential, the synaptic vesicles fuse with the presynaptic membrane 
and release glu into the synapse.  
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1.3 Neurochemical measurements and analytical challenges with 
GABA and glutamate 
The measurement of amino acid neurotransmitter levels in different 
brain regions is crucial to investigate the underlying mechanism and 
design effective therapies for associated neurological diseases. 
Microdialysis is one method used to measure neurotransmitter levels. This 
technique is useful for in vivo monitoring of extracellular levels of 
neurotransmitters present in the brain. Alternately, neurotransmitters can 
be measured in vitro using brain slices or punches which predominantly 
give the intracellular levels of neurotransmitters.    
Analytical challenges with GABA and glutamate 
  Since the neurotransmitter levels in the extracellular space 
fluctuate rapidly, a method with improved temporal resolution is required 
for accurate measurement of extrasynaptic neurotransmitter levels. 
Although some researchers have obtained fast temporal resolution using 
capillary electrophoresis (CE) and microfluidics, still in most 
neurochemical laboratories HPLC is the most popular instrument to 
analyze microdialysis samples due to commercially availability and easy 
instrumental setup. However, it is very challenging to improve the 
temporal resolution with HPLC due to slower separation compare to CE 
and microfluidics. Thus, the coupling of this sampling method to HPLC 
with shorter run time is desired.   
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Detection of amino acid neurotransmitters poses an analytical 
challenge, as they are not naturally electroactive and most amino acids do 
not possess fluorescent or strong UV absorbance characteristics. To 
circumvent this problem, pre-column derivatization is used to make them 
electroactive or fluorescence. 
Most pre-column derivatization for glutamate and GABA detection 
uses ortho-phthaladehyde (OPA)/ β-mercaptoethanol (βME) (Figure 1-
5A.)5,6 However, several studies have shown that the GABA OPA/βME 
derivative is relatively instable.7,8,9,10 An excess of underivatized OPA can 
electrophilically attack the isoindole ring system and enhance the 
autoxidation of the product9. Alternatively, 3-mercaptopropionic acid, 
tertiary butylthiol, and sodium sulphite have been used instead of βME to 
make the OPA derivative more stable since they have less oxidizing power 
than βME.11,12 As an alternative reagent to OPA, naphthalene 
decarboxylaldehyde (NDA)/cyanide ion (CN-) has been developed because 
of its increased stability and higher yield of fluorescent intensity (Figure 1-
5B).7  
Previous studies have shown that simultaneous determination of 
both glutamate and GABA required run times up to 60 min, to separate 
GABA from other co-eluent peaks. However, significant research 
advancements with the conventional C18 pack column have been made, 
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and run time has been improved from 20 to 30 min to about 10 min.7,8, 13,6 
One approach that has been used recently to decrease run time is to use a 
monolithic column for glutamate and GABA separation.14 A monolithic 
column maintains a lower backpressure even when system conditions are 
operated at high flow (typically > 1 mL/min) rates due to the higher 
porosity of these columns, which is about 80% greater than a 
conventional C18 packed column. Additionally, the higher porosity of silica 
monolithic columns provides a greater surface area, leading to better 
separation of small molecules, such as amino acids. Since monolithic 
columns can be operated at higher flow rates without loosing separation 
efficiency compared to packed columns, higher sample throughput, one of 
the demand in the amino acid assay in microdialysis samples can be 
achieved.14  
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Figure 1-5. General reaction scheme for the formation of fluorescence 
active isoindolic products from amino acids with OPA and NDA. (A) The 
reaction of OPA with a primary amino acid in the presence of βME. (B) The 
reaction of NDA in the presence of cyanide.    
CHO
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+ R NH2 + CN- NR
CN
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Microdialysis 
 Microdialysis is a perfusion-based sampling method that permits 
small biochemicals to pass through a semi-permeable dialysis membrane 
down their concentration gradient (Figure 1-6). In the brain, microdialysis 
is used to measure changes in neurotransmitter levels in the extracellular 
space of intact, living tissue. An effective in vivo sampling method to 
monitor neurotransmitters in the brain should provide chemical 
versatility, adequate spatial resolution to permit detection in small, 
distinct brain regions, and fast temporal resolution to detect rapid 
changes in extraneuronal neurotransmitter levels. A main advantage of 
microdialysis over other techniques to measure neurotransmitters in vivo, 
such as positron emission tomography (PET), are that this technique has 
multi-analyte capability, conferred by its ability to be coupled to high 
performance liquid chromatography (HPLC) or capillary electrophoresis 
(CE).15 An additional advantage of microdialysis over other in vivo 
analytical techniques is that it can be used to estimate extracellular basal 
levels of neurotransmitters. However, since the extraneuronal 
concentrations of most neurotransmitters are extremely low in the brain, 
it is critical to couple microdialysis with highly sensitive analytical 
techniques.      
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Figure 1-6. Schematic of a microdialysis probe 
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Microdialysis was developed in 1974 by Ungerstedt and Pycock, who 
introduced a perfusion device, called a dialytrode, which consisted of two 
tubes connected to a dialysis membrane.16 Since then, this technique has 
been refined and widely used in brain research to measure the dynamic 
changes of neurotransmitters. The microdialysis sampling technique relies 
on a small probe inserted into tissue to sample small solutes.17 A 
microdialysis probe consists of a cylindrical semi-permeable membrane, 
typically made from cuprophan, which is connected to an inlet and outlet 
tubing.17 For example, the molecular weight cut-off of the dialysis 
membrane that we use is 6 kDa. Since the dialysis membrane is 
hydrophilic and porous, diffusion occurs through the water space in the 
membrane, greatly increasing the mass transport of the analyte across the 
membrane.17 
Once a probe is introduced to a biological matrix, it is constantly 
being perfused with artificial cerebrospinal fluid (aCSF). ACSF is iso-
osmotic to the extracellular fluid of the tissues being sampled. The 
perfusion medium is delivered at a constant flow rate using syringe pumps 
(Figure 1-7). When sampling from a freely-moving animal in vivo, the 
animal is housed in an open container and the probe is connected to a 
liquid swivel, which allows for free movement of the animal.  
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Microdialysis sampling relies on the principles of diffusion and size 
exclusion. Thus, the ionic strength and composition of the perfusion 
medium should closely resemble the extracellular fluid, to prevent the loss 
of fluid from either the perfusion medium or the extracellular fluid.39 
Small molecules, with a molecular weight below the membrane cut-off, 
diffuse down their concentration gradient through the membrane into the 
perfusion medium. The resulting dialysate is either collected for later 
analysis or transported directly to an on-line analytical system. Since the 
microdialysis probe diameter is much larger (size of our probe is ~ 240 
µm) than the synaptic cleft, it can not directly monitor changes in 
neurotransmitters at the synaptic level. Rather, it can be used to detect 
changes in neurotransmitters from the vicinity of the synaptic cleft, 
referred to as the extrasynaptic space. As a result, dialysis levels of a 
neurotransmitter represent the average concentration of the target 
neurotransmitter in that brain area.     
One of the critical factors that can impact the effectiveness of 
microdialysis sampling is analyte recovery. Recovery can be represented in 
terms of absolute recovery, which is the mass of analyte collected over a 
certain time period, or relative recovery, which is the concentration of 
analyte in the dialysate divided by the concentration in the sample 
media.29 Numerous factors can affect the recovery of analytes through the 
microdialysis probe such as molecular weight cutoff of the dialysis 
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membrane, temperature of the tissue, and membrane materials. However, 
the focus here will be on flow rate, which the experimenter can directly 
control. Recovery rate is impacted by perfusion flow rate, such that a 
higher flow rate will lead to higher absolute recovery and lower relative 
recovery. This is due to the fact that a higher flow rate will shorten the 
time an analyte has to reach equilibrium at the probe surface. As a result, 
a flow rate which gives adequate relative recovery and absolute recovery to 
meet the instrument concentration detection limit and mass detection 
limit should be selected. Although the smaller diameter probes minimize 
tissue damage and improve spatial resolution, this modification negatively 
impacts the recovery of an analyte by reducing the surface area of the 
membrane.17  
Microdialysis samples can be analyzed either on-line or off-line. An 
on-line method requires a rapid and analytical method, since dialysate 
samples are continuously being collected for a given period of time and 
then automatically injected on to the analytical system. In comparison, 
samples are collected in a separate step in off-line assays and stored for 
later analysis. Although on-line analysis of samples allows for detecting 
the analytes during the experiment with minimal sample handling, off-line 
analysis is useful for assays that are slow due to long derivatization time 
or require greater amount of time to separate the analytes. While smaller 
fractions can be collected to increase the temporal resolution of offline 
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assays, the mass detection limit of the analysis instrument is critical as 
the amount of analyte per sample is decreased.15 Thus, increased 
temporal resolution requires the coupling of microdialysis with analytical 
instrumentation that has a high sensitivity and is capable of high 
throughput. In an effort to improve temporal resolution of microdialysis 
sampling, researchers have coupled microdialysis with capillary liquid 
chromatography, capillary electrophoresis, and microfluidics.18,12,19 
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Figure 1-7. Schematic of the basic components to a microdialysis 
experimental setup. 
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Tissue Content  
Although microdialysis is useful for in vivo monitoring of 
extraneuronal neurotransmitter concentrations, it is also important to 
quantitate the intracellular levels of neurotransmitters using dissected 
brain regions of interest.  It has been showed that between 70 and 80% of 
total tissue level GABA serve neurotransmitter function.7 Total tissue level 
neurotransmitter levels predominantly are reflective of intraneuronal 
stores, which comprises of the amino acids levels within vesicles or glial 
cells. Unlike in vivo microdialysis, tissue content is an ex vivo technique. 
The animal is sacrificed and the brain is rapidly harvested. The brain is 
then dissected into discrete brain regions of interest. Tissue content 
provides a global perspective of intracellular neurotransmitter stores 
within discrete brain regions.  
1.4 Research objectives 
 The analytical objective of the research described in this thesis is to 
develop and optimize a fast method using HPLC to rapidly measure the 
concentrations of GABA and glutamate in microdialysis samples. The first 
neurochemical objective is to determine the effect of several endogenous 
and exogenous factors, such as brain-derived neurotrophic factor (BDNF), 
alcohol, and age, on the neuronal levels of striatal GABA and glutamate. 
The second neurochemical goal is to determine if excess exposure to 
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manganese influenced striatal GABA and glutamate levels compared to 
saline-treated mice. Finally, analysis of GABA and glutamate in brain 
tissues of selected brain regions by HPLC also were done to compare the 
concentration of GABA and glutamate with the previously reported values 
obtained by magnetic resonance spectroscopy (MRS) with the purpose of 
validating MRS as an analytical method to measure amino acid 
neurotransmitters. 
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CHAPTER TWO 
 Materials and Methods 
2.1 Introduction 
 The focus of this chapter is to illustrate the methods used to 
conduct the research described in this thesis. The separate sections will 
describe and explain the techniques for animal surgery, microdialysis 
sampling, and optimization of analyte detection with high performance 
liquid chromatography (HPLC). Additionally, intracellular levels of 
glutamate and GABA will be analyzed from mouse brain tissue extracts by 
HPLC and these tissue concentrations will be compared to those 
previously obtained in the laboratory of Dr. Galloway (Department of 
Psychiatry and Behavioral Neurosciences and Anesthesiology, Wayne 
State University) using proton magnetic resonance spectroscopy (1H-MRS).  
2.2 Reagents 
Napthalene-2,3-dicarboxyaldehyde (NDA), di-sodium hydrogen 
orthophosphate (Na2HPO4), and ethylenediaminetetraacetic acid (EDTA) 
were purchased from Fluka (Switzerland). Glutamate (Glu), and GABA 
were obtained from Sigma-Aldrich (St Louis, MO). O-Phthaldialdehyde 
(OPA) was obtained from Alfa Aesar (Germany). Sodium chloride (NaCl), 
sodium phosphate monobasic (NaH2PO4), sodium bicarbonate (NaHCO3), 
calcium chloride (CaCl2), and boric acid from EMD chemicals (Japan). 
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Potassium chloride (KCl), magnesium chloride (MgCl2), HPLC-grade 
methanol and ultrafiltered water from Fisher scientific (Fair Lawn, NJ). All 
aqueous solutions were filtered through Millipore 0.22 µm membrane 
filters. 
  2.3 Animals  
Wildtype (BDNF WT) mice, BDNF+/- (heterozygote) mice, and male 
C57Bl/6J mice were purchased from Jackson Laboratories (Bar Harbor, 
ME). A colony of BDNF WT and BDNF+/- mice was maintained in-house at 
Wayne State animal care facilities. To verify the presence of the transgene, 
genotype identification by polymerase chain reaction (PCR) from their tail 
tissues were done. Approximate age of mice used in these experiments 
was 8-16 weeks old. Mice were housed in groups of 5 to 10 animals per 
cage with food and water ad libtum on a 12-hr light-dark cycle. 
Experimental protocols adhered to the National Institutes of Health 
Animal Care Guidelines and were approved by the Wayne State University 
Institutional Animal Care and Use Committee. 
2.4 Stereotaxic Surgery 
  Adult male mice were anaesthetized with 2,2,2-tribromo-ethanol/2-
methyl-2-butanol (Avertin) administered in a volume 23 mL/kg by 
intraperitoneal (i.p.) route.20 The eyes were protected with sterile 
ophthalmic ointment during surgery. The skin over the skull was shaved, 
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sterilized with Betadine and alcohol, and incised. The exposed skull was 
cleaned and dehydrated with 10% hydrogen peroxide (H2O2). Mice were 
placed on a stereotaxic frame equipped with a palate adapter and two burr 
holes were drilled. One hole was used to insert the guide cannula 
(CMA/Microdialysis AB, Chlemsford, MA) and the second was used for to 
insert a bone screw (BASi, West Lafayette, IN) for anchoring. In all these 
experiments, the guide cannula was targeted to the dorsal striatum 
(caudate-putamen; CPu) using coordinates (anterior + 0.8, lateral +1.3, 
ventral -2.5 from Bregma) determined from the mouse brain atlas and 
further refined by empirical determination.21 The guide cannula was 
secured to the skull with dental cement (CO-ORAL-LTE DENTAL Mfg. Co., 
Diamond springs, CA). At the end of the experiment, animals were 
sacrificed and the brain was rapidly removed and sectioned using a 
Vibratome (Vibratome, St. Louis, MO) to identify probe location. The 
location of the dialysis probe was visually inspected from the coronal 
slices (300 µm) to confirm the placement of the probe was indeed in the 
dorsal CPu (Figure 2-1). 
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Figure 2-1. A cartoon of a mouse coronal brain slice illustrating proper 
placement of the microdialysis probe in the dorsal striatum (CPu).22     
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2.5 In vivo microdialysis  
Four microdialysis experiments were conducted to evaluate the 
effect of 1) BDNF, 2) acute consumption of ethanol, 3) exposure to 
manganese, and 4) age on extracellular levels of GABA and glutamate. In 
all the following experiments, a microdialysis probe (2 mm length x 240 
µm diameter cuprophan, 6000 Da MW cutoff) was inserted into the guide 
cannula in the CPu following surgical recovery (~ 6 hrs). The probe was 
perfused overnight with artificial cerebrospinal fluid (aCSF; 147 mM NaCl, 
3.5 mM KCl, 1.0 mM CaCl2, 1.2 mM MgCl2, 1.0 mM NaH2PO4, 2.5 mM 
NaHCO3, pH ~ 7.4) at a flow rate of 0.7 µl/min. After a 14-h equilibration 
period, microdialysis samples were collected. The dialysate samples 
collected off-line were stored at -80°C until they were derivatized for 
analysis by HPLC.  
Experiment 1: To evaluate the effects of high K+ on the release of glutamate 
GABA in BDNF WT and BDNF+/- mice.  
Six baseline samples were collected from either BDNF WT or 
BDNF+/- mice at 10-min intervals followed by a 20-min perfusion of high-
potassium (120 mM) aCSF (30.5 mM NaCl, 120 mM KCl, 1.0 mM 
NaH2PO4, 1.2 mM MgCl2.H2O, 1.0 mM CaCl2, pH ~ 7.4).23 After the 
perfusion of high-potassium aCSF, samples were collected with normal 
aCSF every 10 minutes for 2-h.  
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Experiment 2: To evaluate the effects of ethanol on striatal extracellular 
concentrations of GABA and glutamate in BDNF WT and BDNF+/- mice.    
Three baseline samples were collected from either BDNF WT or 
BDNF+/- mice at 10-min intervals. The mice were then administered saline 
(0.9% NaCl, i.p.) and samples were collected every 10 min for the next 40 
min. After collection of the fourth saline sample, mice were administered 
ethanol (2 g/kg, i.p.) and 10-min samples were collected for the next two 
hours.  
Experiment 3: To evaluate the effect of manganese exposure on the 
extracellular concentration of GABA in the CPu. 
Prior to dialysis surgery, mice were injected subcutaneously with 
either 0.1 mL of manganese (II) chloride tetrahydrate (MnCl2.4H2O; 50 
mg/kg) or 0.9 % NaCl. Mn treatment was repeated every third day for a 
week (days 1, 4, and 7). Surgery for guide cannula implantation in the 
CPu was performed on either day 8, 14, or 28, which was 1, 7 or 21 days 
following the last Mn treatment. Following probe insertion and a 10 h 
equilibration period, five baseline samples were collected every 10 min.  
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Experiment 4: To evaluate the effect of age on the extracellular 
concentrations of glutamate and GABA in the CPu in mice deficient with 
BDNF. 
Stereotaxic surgery for guide cannula implantation was performed 
on BDNF WT and BDNF+/- mice at 18 months of age. Basal and 
potassium-stimulated levels of glutamate and GABA in the CPu were 
monitored following probe insertion as outlined in experiment 1. 
Derivatization procedure of dialysis samples 
Stock standards of NDA (6 mM) in 50:50 acetonitrile (CH3CN) and 
borate buffer (0.1 M, pH 9.5), KCN (10 mM) in borate buffer, and amino 
acid standards (10 mM) in aCSF were prepared weekly and stored at 4ºC. 
The amino acids were derivatized by adding: 20 µl of borate buffer (0.1 M), 
5 µl of KCN (10 mM), and 5 µl of NDA (6mM) to 7 µl of standard solution 
or dialysate sample. The resulting mixture was vortexed and allowed to 
proceed at room temperature in the absence of light for approximately 10-
15 min, and immediately afterward 20 µl of the derivatization product was 
injected onto the HPLC.  
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 2.6 Mouse brain tissue levels of GABA and glutamate 
Tissue collection 
 Unanesthetized male mice (8 to 16 weeks old) were sacrificed by 
cervical dislocation. The brain was immediately removed, placed on an ice-
cold matrix, and sectioned into 2 mm thick slices. Several tissue punches 
(2.1-mm diameter, approx. wet weight of 4 mg) were microdissected from 
each slice to isolate various brain regions, including the cerebellum (CB), 
nucleus accumbens (NAc), striatum, and hippocampus (Figure 2-2). The 
punches were immediately frozen on dry ice, placed in 1.5 mL 
microcentrifuge tube, and stored at -80ºC for later analysis with HPLC.   
Sample preparation procedure 
 Tissues were removed from the freezer, weighed, and then 
homogenized with 80 µl of 50 µM EDTA in 400 mM HClO4 solution. The 
homogenized tissue samples were neutralized with 0.1 M borate buffer 
(1:10) and centrifuged (14,000 rpm, 30 min, 4 ºC). The supernatant (100 
µl) was removed and placed in a microcentrifuge tube for the 
derivatization.    
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Figure 2.2. Representative coronal dissection slices with 2 mm thickness. 
Circles on brain slices indicate where tissue punches for discrete brain 
regions are approximately taken. Key for brain regions of interest: AST, 
anterior striatum; NAc, nucleus accumbens; HC, hippocampus; CB, 
cerebellum. Photo courtesy of Dr. Matthew Galloway, Wayne State 
University School of Medicine.   
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Derivatization procedure 
The derivatization procedure was based on a protocol previously 
described by Clarke et al. (2007).13 Briefly, 100 µl of either standard or 
sample supernatant was added to a solution containing 0.1 M borate 
buffer (900 µl, pH 9.5), 10 mM potassium cyanide (200 µl) and 6 mM  NDA 
(200 µl). The samples were then vortexed and the reaction proceed for 15 
at ambient temperature in the absence of light. The derivatization product 
(20 µl) was injected onto the HPLC system.      
2.7. Detection of amino acid neurotransmitters in dialysis samples 
Spectrofluorophotometer experiment 
Fluorescence intensity comparison of o-phthalaldehyde (OPA) and 
naphthalene-2,3-dicarboxaldehyde (NDA) were performed using a 
Shimadzu RF-5301PC spectrofluorophotometer (Shimadzu, Columbia, 
MD). Excitation wavelengths of OPA and NDA derivatives were set at 337 
and 420 nm, respectively. Emission intensity of NDA and OPA derivatives 
were measured at the range of between 400 – 600 nm and 300 – 600 nm, 
respectively.11,13 
Fluorescence experiments were performed using a quartz cell. The 
amino acids, GABA and glutamate, were derivatized with either NDA or 
OPA and the duration and intensity of the fluorescent signal was 
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monitored. To derivatize the amino acids with NDA, 0.7 mL of the amino 
acid standard (< 1 µM) was added to working solution containing 0.1 M 
borate buffer (pH 9.5), 10 mM KCN, and 5 mM NDA.24 The OPA 
derivatization protocol was based on a method described by Rowley et al.55 
Briefly, 0.08 M OPA was prepared by dissolving OPA (22 mg) in 0.5 mL of 
absolute ethanol and 0.9 mL of sodium tetraborate buffer (0.1 M, pH 
10.4). This solution was prepared daily and immediately reacted with a 1 
mL of a GABA or glutamate standard in a quartz cell. 
HPLC equipment and conditions 
The binary gradient HPLC system was constructed using two 
Shimadzu LC-20AD HPLC pumps (Shimadzu, Colombia, MD) connected 
with a mixer, on-line degasser, and high pressure flow channel selection 
valve. Mobile phase A consisted of 0.1 M Na2HPO4 in 50 µM of EDTA (pH 
5.7; adjusted with 6 M HCl), and mobile phase B consisted of 100% 
methanol. The gradient elution was performed at room temperature using 
the following conditions: 0 min 40% B (flow rate of pump B: 0.8 mL/min), 
2.00 min 50% B (flow rate of B: 1 mL/min) for a total flow rate of 2 
mL/min. Dialysate samples (10 µL) were injected onto a Chromolith 
column (RP-18e, 100 x 4.6 mm, EM Science, Germany) for separation of 
GABA and glutamate. Fluorescence intensity of the effluents was 
measured by Jasco FP 2020 fluorescence detector (Jasco, Tokyo, Japan). 
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The excitation and emission wavelengths for NDA-derivatized amino acids 
were set to 420 and 480 nm, respectively. Known standards were used to 
identify and quantify the GABA and glutamate peaks in the HPLC 
chromatogram. Characteristic retention times for GABA and glutamate 
were 4.5 and 1.8 min, respectively. The peak areas of GABA and 
glutamate were integrated with the calibration curve of known standards. 
Concentrations were expressed in nM ± standard error of the mean (SEM).  
2.8 Data analysis 
All data were analyzed using GraphPad Prism 5 software. The 
average concentration of baseline samples were set at 100% and all the 
other value are expressed as percentage of the average of baseline 
samples. To determine if extracellular glutamate and GABA levels are 
significantly different between BDNF WT and BDNF+/- mice a Student’s t-
test was performed. The t-test probability “P” value determines whether 
the compared two means are “different” from each other and the level of 
significance was set at P < 0.05. All values present as means ± standard 
error of the mean (S.E.M). When comparing means of all the mice, the 
data were analyzed by a one-way analysis of variance (AVOVA) followed by 
a Tukey post-hoc test using GraphPad Prism software.  Linear regression 
analysis was done to determine the linearity of calibration curves. 
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CHAPTER THREE 
METHOD OPTIMIZATION 
 While a number of studies have demonstrated the stability and 
fluorescence properties of isoindole products obtained from NDA 
dervitization, the spectrofluoromety studies described in this chapter will 
compare the stability, fluorescence intensity, and the kinetic properties of 
OPA and NDA derivatives of GABA and glutamate. These optimized 
parameters will be applied to determine the concentrations of GABA and 
glutamate in dialysis samples obtained from all microdialysis experiments 
conducted in the CPu of mice.  
3.1 Comparison of glutamate and GABA detection with NDA and OPA 
Fluorescence intensity comparison of OPA and NDA were performed 
as described in section 2.3. The excitation and emission wavelengths for 
OPA derivatives were 337 and 454 nm and NDA derivatives were 420 and 
480 nm, respectively. The fluorescence intensities of OPA and NDA 
derivatives are shown for identical concentrations (1 µM) of GABA (Figure 
3-1A) and glutamate (Figure 3-1B) as a function of time. These profiles 
show a rapid increase in fluorescence intensity for both OPA and NDA 
derivatives due to the rate of formation of isoindolic products. However, 
the plateaus for GABA and glutamate fluorescence emission with NDA and 
OPA were considerably different. Fluorescence intensity of NDA derivatives 
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of GABA and glutamate are about 2.5 and 2 fold higher than that of OPA 
derivatives, respectively. 
The kinetics of GABA and glutamate labeling by NDA was similar, 
and in both cases, the reaction was completed in approximately 20 min. 
After reaching a maximum, the fluorescence intensity of NDA derivatives 
remained stable for about one hour at room temperature. Although the 
fluorescence intensity of OPA derivatives were considerably lower 
compared to NDA derivatives, the OPA derivatization reaction was 
completed in less than 5 min. The life-time of the fluorescence for OPA 
products was also short-lived and started to decrease 25 min after 
reaching the maximum. Together, these data demonstrate NDA derivatives 
of both GABA and glutamate have a higher fluorescence intensity and 
stability compared to OPA derivatives, thus confirming the higher 
sensitivity of NDA derivatization to detect amino acids. 
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Figure 3-1. Fluorescence intensities of isoindole derivatives of (A) GABA  
and (B) glutamate formed by OPA (open symbols) or NDA (closed symbols) 
derivitization. Fluorescence intensity is define as arbitrary units (a.u).  
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Method Validation 
The linearity was determined for glutamate (Figure 3-2A) and GABA 
(Figure 3-2B) standard calibration curves in the range of 5 to 200 nM. The 
correlation coefficient yielded by linear regression analysis was 0.9995 
and 0.9980 for GABA and glutamate, respectively. The limit of detection 
(LOD) which is three times signal to noise ratio for GABA and glutamate 
(20 µl injection volume) was 6 nM and 10 nM, respectively. The 
repeatability of the optimized method was determined by injecting 50 nM 
and 100 nM GABA and glutamate standards repeatedly five times. The 
repeatability was 2.4% (R.S.D) for GABA and 3.5% (R.S.D) for glutamate.    
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Figure 3-2. Linear relationship between detector response and the 
amount of glutamate and GABA injected. (A) Calibration curve of 
concentration of glutamate (nM) versus area of corresponding peaks. (B) 
Calibration curve of concentration of GABA (nM) versus area of 
corresponding peaks. 
(nM) 
(nM) 
A 
B 
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3.2 Separation and detection of GABA and glutamate from 
microdialysis samples 
 A binary gradient was used to separate glutamate and GABA for 
simultaneous HPLC detection. The mobile phase composition was based 
on a study by Clark et al. (2007) with modifications.13 GABA and 
glutamate peak separation was optimized by altering the percentage of 
methanol in the gradient profile; pH of the sodium dihydrogen phosphate 
buffer (buffer A); and the flow rate. The retention of glutamate, but not 
GABA, was sensitive to pH changes in buffer A. Increasing the pH of buffer 
A at 0.1 intervals from 5.3 to 5.9 enhanced the separation of glutamate, 
with optimal separation of glutamate at pH 5.7. The detection of GABA 
from striatal microdialysis samples was challenging, since GABA is in low 
concentration in the dorsal striatum (CPu) and often co-elutes with non-
specific peaks that also have late retention times. Therefore, GABA 
separation was considered an end-point for the optimization of amino acid 
detection in dialysis samples and was achieved by changing the gradient 
proportionality. To better resolve GABA from other co-eluting peaks, the 
percentage of methanol used in the gradient was increased from 40%, 
which is optimal for glutamate detection, to 50% methanol. The optimum 
flow rate for glutamate and GABA detection with this method was found to 
be 2 mL/min and all the runs was performed at ambient temperature with 
a monolithic column. Representative HPLC chromatograms (Figure 3-3) 
show the separation of glutamate and GABA from standards (100 nM; Fig. 
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3-3A) and from dialysis samples (Fig. 3-3B) using these optimized 
conditions. 
Samples were injected every 15 min following completed NDA 
derivatization. The basal levels of GABA and glutamate in the CPu of 
C57Bl/6 mice using these optimized conditions were 63 ± 11 nM and 440 
± 64 nM, respectively. These values are comparable with previously 
reported values where GABA and glutamate concentration in CPu were 
approximately 34 and 400 µM, respectively.26   
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Figure 3-3. Representative chromatograms illustrating the separation of 
glutamate and GABA from (A) standards and from (B) microdialysis 
samples from the dorsal striatum (CPu) of mice.  
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CHAPTER FOUR 
MICRODIALYSIS EXPERIMENTS 
Four different microdialysis experiments were conducted to evaluate 
the effects of low endogenous levels of BDNF, ethanol, age, and Mn on 
extracellular GABA and glutamate in CPu of mouse brain. To analyze the 
microdialysis samples for GABA and glutamate optimized HPLC 
parameters described in chapter three were used.  
Experiment 1: To evaluate the effects of high K+ on the release of glutamate 
GABA in BDNF WT and BDNF+/- mice.  
  Although the concentration of glutamate and GABA are higher than 
that of monoamine neurotransmitters in the microdialysis samples it does 
not necessarily indicate that they have neuronal origin. To demonstrate 
that the extracellular glutamate and GABA levels measured by 
microdialysis are neuronally-derived, neurons were depolarized using high 
K+ (120 mM KCl) aCSF. High K+ perfusion stimulates neuronal firing by 
depolarizing the nerve terminals in the vicinity of microdialysis probe. 
 To evaluate the effect of BDNF on K+-stimulated neuronal firing in 
the CPu, a similar high K+ aCSF perfusion experiment was performed in 
BDNF heterozygous (BDNF+/-) mice. BDNF+/- mice lack one copy of the 
BDNF gene and hence have an approximate 50% reduction in BDNF 
levels.23 BDNF belongs to the neurotrophin family of growth factors, which 
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also includes nerve growth factor, neurotrophin 3, and neurotrophin 4. 
BDNF, a 27 kDa homodimeric protein, is the most abundant neurotrophic 
factor in the brain.1 In general, neurotrophins are synthesized and 
released by neurons to support neuronal growth, differentiation, function, 
.survival and plasticity.1,30 Several lines of evidence also suggest there is 
an important interaction between BDNF and amino acid neurotransmitter 
systems. For instance, glutamatergic and GABAergic neurotransmission 
increased BDNF mRNA expression in the hippocampus.30 In turn, BDNF 
modulates transmitter release in both glutamate and GABAergic 
synapses.30  
 The elevation in the extracellular levels of GABA and glutamate following 
20 min high K+ stimulation in both wildtype and BDNF+/- are shown in the 
representative chromatogram in Figure 4-1. Stimulation with high K+ 
aCSF resulted in a 25- fold and 4-fold increase in GABA (Figure 4-2A) and 
glutamate (Figure 4-2B) levels, respectively in CPu in both types of mice. 
Two way analysis of variance (ANOVA) revealed that there was a 
significant effect of time for both GABA (F14,195=7.29) and glutamate 
(F14,210=10.6) indicating high K+ stimulated enhanced release. The amount 
increased in GABA and glutamate by K+ stimulation compare to their 
basal levels are consistent with previously reported data.11,27   
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Figure 4-1. Representative chromatograms from pre- and post-potassium 
stimulation. Effect of high K+ stimulation on the extracellular levels of 
amino acid neurotransmitters measured by microdialysis in the dorsal 
striatum (CPu) of mice. The pink line on the chromatogram shows a 
baseline sample before K+ stimulation and black line shows the third 
dialysate sample collected 40 min following K+ perfusion.   
 
Glu 
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Experimental variability in stimulated levels of neurotransmitters is 
often attributed to the amount of K+ that diffuses from the perfusate to the 
brain tissue, which depends on the membrane tortuosity and perfusion 
flow rate.28 The maximum effect of K+ stimulation on extracellular GABA 
and glutamate was observed about 40 min after high K+ aCSF perfusion. 
K+-stimulated release of glutamate was smaller than the effect of K+ on 
GABA. This difference may be due to the rapid activation of glutamate 
transporters and subsequent re-uptake of glutamate back into 
presynaptic terminals in surrounding tissue by high concentrations of 
K+.28,29 
          No difference was observed in the basal levels of either GABA or 
glutamate in the CPu between wildtype and BDNF+/- mice (Figure 4-3A). In 
BDNF+/- mice, the basal levels of GABA and glutamate were found to be 59 
± 27 nM and 290 ± 62 nM, respectively. K+-stimulated GABA release was 
also unaltered in the CPu of BDNF+/- mice compared to wildtype mice 
(Figure 4-3B). Alternatively, a two-tailed t-test revealed a significant 
difference in K+-stimulated release of glutamate between wildtype and 
BDNF+/- mice (t=3.415, p<0.01) (Figure 4-3B). These data are consistent 
with previous studies, which reported that BDNF enhanced glutamate 
release but either reduced or had no effect on GABA transmission.32, 33 
BDNF may enhance the release of glutamate through activation of the 
TrkB receptor, which in turn activates phospholipase C (PLC) and 
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produces inositol triphosphate (IP(3)). PLC and IP(3) can initiate the 
release of Ca2+ from intracellular stores and thereby enhance the release 
of neurotransmitters from presynaptic vesicles.34 
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Figure 4-2. Extracellular basal and stimulation-induced GABA and 
glutamate levels determined by in vivo microdialysis in BDNF WT and 
BDNF+/- mice. The response of elevated K+ (120 mM) on extracellular (A) 
GABA and (B) glutamate levels in the dorsal striatum (CPu) of wildtype 
(n=8) and BDNF+/- (n=7)mice.  
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Figure 4-3. Summary of extracellular basal and stimulation-induced 
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined 
by in vivo microdialysis in BDNF-deficient mice. (A) Mean baseline levels of 
GABA and glutamate not corrected for probe recovery in wildtype (n=8) 
and BDNF+/- (n=8) mice. (B) Area under the curve analysis of high K+ (120 
mM) stimulation of GABA and glutamate in the CPu in wildtype (n=8) and 
BDNF+/- (n=8) mice. Data are mean ±SEM. * p < 0.05 compared to wildtype 
mice (two-tailed t-test). 
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Experiment 2: To evaluate the effects of ethanol on striatal extracellular 
concentrations of GABA and glutamate in BDNF WT and BDNF+/- mice.     
Alcoholism is a major health problem among people worldwide. In 
the United States, it is estimated that over 14 million Americans suffer 
from chronic neuropsychiatric disorders related to alcoholism.35 Many 
neurotransmitter systems, including amino acid neurotransmitters, are 
affected by ethanol. Ethanol is a small molecule that interacts with 
various ligand-gated ion channels, GABA receptor complexes, and 
glutamate receptors. For instance, ethanol has been shown to enhance the 
function of GABAA receptors as well as reduce the function of NMDA 
receptors.36,37  In the case of GABA, it has been suggested that activation 
of GABA autoreceptors after ethanol administration would reduce the 
output of GABA.38 While some studies have shown that an acute ethanol 
injection (2g/kg) reduces extracellular levels of GABA and glutamate, 
others have reported this treatment has no effect on either GABA or 
glutamate transmission.38,39,40 Since most of these studies were conducted 
in the rat nucleus accumbens, the purpose of the current study was to 
further evaluate the effect of ethanol on dorsal striatal extracellular GABA 
and glutamate levels in mice.  
In this study, both wildtype and BDNF+/- mice were treated with a 
systemic injection of 2 g/kg ethanol (i.p.), which was shown to elicit 
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behavioral changes acutely in animals.41 As described in Experiment 2, 
BDNF+/- mice have low endogenous levels of BDNF and were used in this 
experiment to evaluate the effect of reduced BDNF levels on ethanol-
evoked changes in GABA and glutamate transmission. After the collection 
of three baseline samples (30 min), mice received a saline injection prior to 
ethanol administration to observe if animal handling during the injection 
would have a stress-induced effect on the extracellular levels of glutamate 
and GABA. Four dialysis samples were collected following the saline 
injection. Overall, there was no difference in the levels of either 
extracellular GABA or glutamate after a saline injection (Figure 4-4 A and 
B). Analysis of the dialysis samples collected following ethanol 
administration revealed that the ethanol-induced glutamate levels were 
unaltered in both wildtype and BDNF+/- mice (Figure 4-4B). Alternatively, 
ethanol promoted the release of GABA in both wildtype and BDNF+/- mice 
30 min after injection (Figure 4-4A). Ethanol enhanced the extracellular 
level of GABA by approximately 4-fold, which returned to baseline levels 
70 min after the ethanol injection. Although ethanol stimulated GABA 
release in both wildtype and BDNF+/- mice, the peak GABA release is 
slightly reduced in BDNF+/- mice. Following area under the curve analysis, 
the effect of ethanol to increase extracellular GABA was not statistically 
different (t=2.065, p > 0.05) between wildtype and BDNF+/- mice (Figure 4-
5) when evaluated using a t-test.     
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Together, these results indicate systemic ethanol administration has 
no effect on the levels of extracellular glutamate but stimulates an 
increase in the levels of extracellular GABA. While the lack of effect of 
ethanol on glutamate transmission agrees with previous reports40,42 the 
changes in GABA are contradictory to previously reported findings with 
ethanol in the nucleus accumbens (i.e. reductions in GABA output).12,41 
Since the current data were collected in the dorsal striatum, this may 
indicate the effect of ethanol to increase GABA output is regionally 
specific. For instance, it has been suggested that activation of GABAB 
autoreceptors in some brain regions might mask ethanol-evoked 
enhancement of GABA transmission.43  
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Figure 4-4. Saline and ethanol (EtOH)-stimulated extracellular GABA and 
glutamate levels in the dorsal CPu of BDNF deficient mice. (A) 
Extracellular GABA concentration was increased in both WT and BDNF+/- 
mice after an acute injection of ethanol. (B) No difference in extracellular 
glutamate levels between the genotypes (WT n=4; BDNF+/- n =3).   
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Figure 4-5. Area under curve analysis for the GABA peak for wildtype 
(WT; n=4) and BDNF+/- (n=3) after ethanol administration. For area under 
the curve analysis time points from 80 – 150 min were analyzed. Data are 
the means ± S.E.M.  
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Experiment 4: To evaluate the effect of manganese exposure on the 
extracellular concentration of GABA in the CPu. 
 Manganese (Mn) is an essential trace element in the body.  It has 
many important biological roles, such as a co-factor for key enzymes that 
regulate metabolism, reproduction, digestion, blood clotting.50 Unlike 
other trace elements, such as zinc and iron, Mn can accumulate to toxic 
levels in the brain, particularly in individuals with routine occupational 
exposure (i.e. welders, miners, and steel workers).49 Iron (Fe) deficiency is 
another factor that appears to facilitate Mn accumulation.50 Since Mn 
competes with Fe for transport through divalent metal transporters, less 
Fe in the body enhances the absorption of Mn in the tissue. Most studies 
have linked Mn neurotoxicity, which manifest in a syndrome known as 
manganism, with alterations in dopamine neurotransmission.50,51 
However, recent studies have indicated that other neurotransmitters, 
particularly GABA, are affected by Mn accumulation.50,52     
Based upon these previous studies, the effect of Mn accumulation 
on extracellular basal levels and K+ release of GABA was measured in the 
striatum of mice. Administration of 120 mM K+ for 20 min enhance the 
release of GABA in both control and Mn-treated mice at each time point 
after cessation of Mn-treatment (Figure 4-8A,B and C) The extracellular 
concentration of GABA was increased on day 2 following repeated 
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systemic injections of Mn (50 mg/kg) (Figure 4-9A). GABA was 
significantly increased by ~ 22% in Mn treated mice compared to control 
mice on day 2 (t=2.453, p < 0.05). However, extracellular GABA levels were 
similar in Mn treated mice relative to control mice on day 8 and 22 after 
treatment. This finding correlates with the previous observations that Mn 
levels are typically elevated in the brain immediately following Mn  
treatment but return to normal levels by day 14.53, 54 Conversely, area 
under the curve analysis indicates K+-stimulated (120 mM) GABA release 
was unaltered by Mn treatment on any treatment day compared to control 
conditions (Figure 4-9B).  
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Figure 4-8. Extracellular basal and stimulation-induced GABA levels 
determined by in vivo microdialysis in Mn-treated mice The effect of elevated K+ 
(120 mM) on extracellular GABA in mice treated with Mn (n=4) showed no 
difference compared to control (saline treated mice. Stimulated GABA 
levels were measured (A) 2, (B)  8, and (C) 22 days after Mn treated and 
control mice (n=4). 
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Figure 4-9. Summary of extracellular basal and stimulation-induced 
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined 
by in vivo microdialysis in Mn treated mice. (A) Baseline levels of GABA in 
Mn treated (n=4) and control mice (n=4) at 3 discrete time points after Mn-
treatment. (B) Area under curve for the K+ stimulated release of GABA in 
Mn treated and control mice. 
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In summary, these data suggest elevated levels of Mn in the brain 
enhance the extracellular levels of GABA in the striatum, without altering 
stimulated release. The elevated extracellular GABA levels in the dorsal 
striatum agrees with a previous finding where an increase in extracellular 
GABA levels in striatum was seen in rats exposed to a high Mn diet.50 
Previous studies have suggest that Mn upregulates GABAA ionotropic 
receptors and also dose dependently bind to GABAB autoreceptors and 
inhibit it’s function.55,56 Therefore, increased levels of extracellular GABA 
maybe due to regulation of GABAB autoreceptor function and upregulation 
of GABAA receptor function by Mn.   Although it has been shown that Mn 
exposure reduces GABA tissue levels in the striatum in rats54, according 
this result there is no significant difference in high K+ stimulated release 
in GABA in Mn treated mice compare to controls.   
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Experiment 4: To evaluate the effect of age and low endogenous BDNF 
levels on the extracellular concentrations of glutamate and GABA in the 
CPu. 
 Despite the brain’s intrinsic compensatory processes, it has been 
shown functional and morphological changes in the brain with age. These 
age-related changes include loss of neurons and structural proteins as 
well as a reduction in the levels of neurotransmitters, their precursor 
molecules, and receptor binding sites, and reduction of the activity of 
enzymes involve in the synthesis of neurotransmitters.44,45 Often, these 
changes are directly linked to age-associated abnormalities, such as loss 
of motor function and deficits in learning and memory.46 Sometimes these 
changes are brain-region specific. In the case of amino acid 
neurotransmitters, rodent aged-studies have shown a decrease in 
glutamate and GABA receptors in the hippocampus, a reduction of the 
GAD enzyme primarily in cortex and thalamus, and a decrease in the 
number of presynaptic terminals.47 Overall, these changes would indicate 
amino acid transmission is reduced in the aged brain. Indeed, 
Huntington’s disease has been associated with the loss of GABA signaling 
in the striatum.48 
In light of the studies demonstrating age-related changes in 
glutamate and GABA, the current study compared the basal and 
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stimulated levels of both amino acid neurotransmitters in the striatum of 
young (approximately 3-6 months old) and aged (18 months old) mice. In 
aged mice, there was a significant increase (t=5.547, p <0.001) in the 
basal levels of extracellular GABA (340 ± 50 nM) compared to adult mice 
(63 ± 11 nM) (Figure 4-7A). Alternatively, no significant difference was 
observed in the baseline levels of extracellular glutamate between adult 
and aged mice (Figure 4-7A). Alteration of extracellular GABA and 
glutamate levels in the CPu of young and aged mice were measured 
following high K+ stimulation. The release of both GABA and glutamate in 
aged mice after K+ stimulation was considerably less compare to that of 
young mice (Figure 4-6A and B). Two way ANOVA revealed that there was 
a significant effect of age for K+ stimulated release of both GABA 
(F1,96=10.32) and glutamate (F1,98=7.45). To compare the potassium-
stimulated release between young and aged mice, area under curve for the 
potassium stimulated release was determined for each mouse (Figure 4-
7B). According to the t-test potassium-stimulated release of both GABA 
(t=2.363, p=0.05) and glutamate (t=3.551, p=0.01) were significantly 
decreased in aged mice compared to young mice with about 60% decrease 
in GABA and 46% decrease in glutamate. Together, this study 
demonstrates basal extracellular GABA levels increase in the CPu with 
age, while stimulated release of both GABA and glutamate were 
attenuated in aged mice compared to young mice. Particularly, this study 
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shows significant age-related changes in both basal and high K+ release 
levels of GABA. Increase level of basal GABA might be due to reduced 
function of GABA transporters and GABA autoreceptors with age. 
Altogether, these data demonstrate altered GABA and glutamate 
neurotransmitter function in CPu in aged mice which may make them 
more susceptible to various age-related neurological diseases.  
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Figure 4-6. Extracellular basal and stimulation-induced GABA and 
glutamate levels determined by in vivo microdialysis in young and aged 
wildtype mice. High K+ (120 mM) aCSF was perfused directly through the 
dialysis probe and  extracellular GABA (A) and glutamate (B) in the CPu of 
wildtype young (n=8) and aged mice (n=4) were evaluaed. Data are the 
means ± S.E.M. 
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Figure 4-7. Summary of extracellular basal and stimulation-induced 
GABA and glutamate (Glu) levels in the dorsal striatum (CPu) determined 
by in vivo microdialysis in young and aged mice. (A) Extracellular basal 
levels of GABA and glutamate in wildtype young (n =8) and aged (n=4) 
mice. ***P <0.001, compare to the adult mice (student’s t-test). (B) Area 
under the curve for the potassium stimulation release of GABA and 
glutamate in wildtype adult and aged mice. Data are the means ± S.E.M. 
**p < 0.001 (two-tailed t-test) 
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CHAPTER FIVE 
ANALYSIS OF TISSUE CONTENT 
 Table 1 summarizes the results obtained for GABA and glutamate 
levels on the frontal cortex, hippocampus, and striatum of male C57BL/6 
mice. Among these three brain regions, frontal cortex shows the highest 
concentration of both glutamate and GABA. Analysis of GABA and 
glutamate tissue content was also performed by the optimized HPLC 
method coupled to pre-column derivatization by NDA (see Chapter 3 ). 
Detector sensitivity was set at low since the intensities for the amino acids 
are high. As previous methods mentioned, one of the amino acid that 
interfere with glutamate detection  in tissue samples is N-acetyl-aspartate 
(NAA).11,12 NAA is known to co-elute with glutamate peak because the 
concentration of NAA is much higher in tissues and its retention is similar 
to glutamate. However, our derivatization method uses NDA, which reacts 
with only primary amino acids and since NAA is a secondary amino acid, 
it was not derivatized by NDA in this method.   
 For NDA-amino acids reaction, pH greater than 9.5 is required. In 
biological samples the amino group of amino acids (-NH2) present as 
protonated (-NH3+). NDA reacts with only nonprotonated NH2 group.12 
Therefore, the NDA reaction requires a buffer having a pH greater than 
9.5, which is the approximate pKa of the amino groups. The problem 
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associated with tissue analysis by NDA was the homogenizing buffer 
contained HClO4, thus the pH of the homogenizing buffer is less than 2 
and adding the derivatizing reagents (NDA, and KCN, and borate buffer at 
pH 9.5) to the homogenate did not derivatize the amino acids in the 
sample. With this homogenizing buffer, which was not sufficiently basic to 
derivatize the amino acids, thus, an additional step was preformed. Borate 
buffer (pH 9.5) was added to the samples after the homogenization to 
make the pH of the sample neutral (~pH 7.0-7.4). Since all the punches 
are approximately same weight (~3 mg), a constant volume (provide 
volume) of homogenizing buffer was added to all the samples  
 Analysis of GABA and glutamate tissue content was done in frontal 
cortex, hippocampus, and striatum. Among these three brain region 
frontal cortex shows the highest concentration of both GABA and 
glutamate. These values are consistent with previous reported values.25,28  
Future work with this preliminary study will compare the tissue content of 
GABA and glutamate tissue levels as measured by HPLC-fluorescent 
detection to values obtained by magnetic resonance spectroscopy. 
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Table 5-1. GABA and glutamate levels from tissue punches obtained from 
the frontal cortex, hippocampus, and striatum of C57Bl/6J mice. Results 
are expressed as mean ± S.E.M.  
 
 
 
 
 
 
 
 
 
Brain region GABA (µM/g) Glutamate (µM/g) 
Frontal Cortex 33.0 ± 2.0 (n=5) 139.0 ± 8.0 (n=5) 
Hippocampus 1.8 ± 0.04 (n=5) 11.0 ±0.019 (n=5) 
Striatum 2.2 ±0.03 (n=5) 3.4 ± 0.2 (n=5) 
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CHAPTER SIX 
Conclusions 
 GABA and glutamate are important amino acid neurotransmitters in 
the central nervous system (CNS), since they have essential roles as the 
major inhibitory and excitatory transmitter systems, respectively. As a 
result, altered levels of GABA and glutamate underlie several neurological 
diseases.6 The ability to measure the dynamics of GABA and glutamate 
transmission, by detecting changes in extracellular and tissue levels in 
different brain regions, will thus lead to a better understanding of the 
etiology of these dysfunctions and effective pharmacotherapies. In 
neurochemistry laboratories, HPLC is a prevalent method used to detect 
neurotransmitters, since it is commercially available and easy to setup. 
One of the challenges in the detection of amino acid transmitters is that 
they are not electroactive or fluoresce. To overcome these chemical 
limitations, pre-column derivatization can be done. This thesis describes 
the optimization of pre-column derivatization of GABA and glutamate by 
NDA/CN- for analysis by HPLC employing a monolithic column. In a direct 
comparison to OPA derivatization, NDA fluorescent products of GABA and 
glutamate were very stable and could be separated in less than 5 min with 
a total sample run time of 10 min.  
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This optimized method was then used to monitor changes in 
extracellular levels of GABA and glutamate in vivo using off-line coupled 
microdialysis. In this thesis, microdialysis was used to study the effects of 
1) high K+ stimulation, 2) low endogenous levels of BDNF, 3) acute 
administration of ethanol, 4) age, and 5) Mn accumulation on GABA and 
glutamate transmission in the CPu of freely-moving mice.  
1. How BDNF influences baseline and stimulated GABA and 
glutamate in the CPu. 
Mice that have approximately a 50% decrease in BDNF showed that 
no differences in extracellular GABA and glutamate levels in the dorsal 
CPu. However, upon a 20 min high K+ stimulation demonstrated that the 
release mechanism is significantly reduced for glutamate only in BDNF+/- 
mice. The BDNF data implicate a role for BDNF to regulate striatal 
glutamate neurotransmission, which are consistent with previously 
published reports. However, when a locomotor-stimulating dose of ethanol 
(2 kg/g) was administered no differences were observed between the 
wildtype and BDNF+/- mice. Although no precise mechanism has been 
identified for how ethanol regulates striatal amino acids level, an acute 
injection of ethanol elevated extracellular GABA in the CPu, while 
glutamate levels were insensitive to ethanol treatment. Further studies are 
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required to better understand how extracellular GABA and glutamate 
levels respond to alcohol in both the dorsal and ventral striatum.  
2. How age influences baseline and stimulated GABA and glutamate 
in the CPu. 
In vivo microdialysis was used to determine whether the effect of age 
selectively alters extracellular GABA and glutamate levels in the dorsal 
CPu. Extraneuronal GABA levels without correction for probe recovery 
averaged over 3 baseline samples per mouse showed a significant increase 
in aged mice. However, there was no difference in extraneuronal glutamate 
levels between the young and aged mice. To investigate whether 
alterations in stimulated GABA and glutamate release might be associated 
with age, high K+ was perfused via reverse dialysis into the striatum 
during the period 30 – 50 minute after baseline sample collection was 
initiated. GABA was maximally elevated ~21-fold above baseline in young 
mice, while a ~6-fold above baseline was observed in aged mice. 
Glutamate was maximally elevated ~3- and 4-fold above baseline in aged 
and young mice, respectively. The age-related declines in potassium-
stimulated extracellular levels of GABA and glutamate suggest these 
neurotransmitters are sensitive to modification in the aging brain. 
However, the finding that basal extracellular levels of GABA but not 
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glutamate are altered in aged mice illustrate that neurotransmitters are 
not always equally sensitive to aging effects.  
3. How manganese exposure effects extracellular concentrations of GABA in 
the CPu. 
Recent studies highlight that excessive exposure of Mn can 
influence a variety of striatal neurotransmitter systems such as dopamine, 
norepinephrine, and GABA.54,55 In vivo microdialysis was used to 
determine whether a sub-acute Mn treatment selectively alters striatal 
extracellular GABA levels. Extraneuronal GABA levels without correction 
for probe recovery showed no difference 8 or 22 days after Mn-treatment. 
However, a significant increase was observed 2 days after a sub-acute Mn-
treatment. These results suggest that a sub-acute Mn treatment have an 
imminent effect on extracellular GABA levels, but that this effect 
dissipates within 6 days. Although an increase in extracellular levels was 
observed in Mn-treated mice, no difference was observed between control 
and treated mice with respect to alterations in stimulated GABA release by 
high K+ aCSF. Taken together, these results suggest that Mn 
accumulation can induce a transient increase in extracellular GABA levels 
that are not affected by robust stimulation on day 2. Further studies are 
required to determine if these significant but transient increases in 
extracellular GABA levels following Mn accumulation are involved in the 
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locomotor deficits associated with Mn neurotoxicity, including 
hyperkinesias, ataxia, and dystonia.50  
  Collectively, this thesis describes the development of a reproducible 
and accurate HPLC-based method, which can reliably be coupled with 
microdialysis to measure biologically relevant changes in extracellular 
GABA and glutamate levels. Interesting the most robust alterations in the 
extracellular striatal GABA and glutamate levels were uncovered in aged 
mice, while a significant decrease in extracellular glutamate levels was 
observed in BDNF+/- mice only after high potassium stimulation, and 
finally a modest increase was observed in extracellular GABA only in Mn-
treated mice. The results within this thesis highlight the importance of 
monitoring amino acid neurotransmitters such as GABA and glutamate 
under various conditions such as low endogenous BDNF levels, age, or 
excess accumulation of Mn by in vivo microdialysis to better understand 
the dynamics of these neurotransmitters.  
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 GABA and glutamate are the predominant inhibitory and excitatory 
amino acid neurotransmitters in the central nervous system (CNS), 
respectively. However, their altered levels cause several neurological 
diseases including Parkinson’s and Huntington’s disease, schizophrenia, 
and epilepsy. It is important to measure their levels in the extra- and 
intracellular environments to better understand and develop improved 
therapeutics that will treat these neurological disorders. The principle aim 
of this study is to study the impacts of different endogenous and 
exogenous factors on the striatal extracellular GABA and glutamate levels. 
The first objective was to develop a method to analyze GABA and 
glutamate using HPLC coupled to fluorescence detection. The second 
objective was to evaluate the effects of BDNF, age, ethanol, and Mn 
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exposure on the striatal GABA and glutamate levels. Using a monolithic 
column, GABA and glutamate were separated in dialysis samples at 2 and 
4.5 minutes, respectively. Low levels of endogenous BDNF, acute 
administration of ethanol (2 g/kg), and age differently affect the GABA and 
glutamate levels. In BDNF+/- mice potassium stimulated release of 
glutamate was significantly reduced while release of GABA was not 
different between wildtype and BDNF+/- mice. Administration of ethanol 
increased extracellular levels of GABA in both wildtype and BDNF+/- mice. 
The impact of age on striatal extracellular GABA and glutamate levels was 
evaluated in mice 3 and 18 months old. Aged mice showed a significant 
reduction in both high K+-stimulated GABA and glutamate release.  
The final study evaluated the effect of a sub-acute Mn treatment on 
striatal extracellular GABA levels, where a modest but significant increase 
in extracellular GABA was observed 2 days after Mn treatment.  Taken 
together, these findings reveal that extracellular GABA and glutamate are 
differentially affected by BDNF, ethanol, age, and Mn.  
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